{"alanine aminotransferase increased": 7.72, "alveolar soft part sarcoma": 2533.51, "amylase increased": 6.4, "ascites": 2.36, "aspartate aminotransferase increased": 6.57, "blood alkaline phosphatase increased": 2.4, "blood bilirubin increased": 10.17, "blood pressure increased": 2.36, "blood thyroid stimulating hormone increased": 11.62, "cardiac failure": 2.18, "clear cell renal cell carcinoma": 479.39, "decreased appetite": 3.34, "diarrhoea": 2.86, "disease progression": 3.48, "drug intolerance": 3.43, "drug-induced liver injury": 10.1, "haemoptysis": 3.16, "hair colour changes": 87.21, "hepatic enzyme increased": 2.67, "hepatic failure": 3.84, "hepatic function abnormal": 9.18, "hepatotoxicity": 25.15, "hyperbilirubinaemia": 11.93, "hypertension": 5.88, "hypertransaminasaemia": 7.1, "hypothyroidism": 8.1, "intestinal perforation": 9.57, "jaundice": 5.1, "liver function test abnormal": 3.37, "liver function test increased": 5.4, "liver injury": 6.17, "malignant neoplasm progression": 30.17, "metastases to bone": 12.42, "metastases to central nervous system": 14.17, "metastases to liver": 11.04, "metastases to lung": 51.22, "metastases to lymph nodes": 17.74, "metastatic renal cell carcinoma": 61.89, "mucosal inflammation": 3.35, "nephrotic syndrome": 5.46, "neutropenia": 2.28, "osteosarcoma metastatic": 1076.44, "palmar-plantar erythrodysaesthesia syndrome": 16.47, "platelet count decreased": 2.95, "pleural effusion": 3.61, "pneumothorax": 39.06, "posterior reversible encephalopathy syndrome": 14.02, "product use in unapproved indication": 12.95, "proteinuria": 9.11, "pulmonary mass": 5.38, "renal cancer": 10.63, "renal cell carcinoma": 31.3, "soft tissue sarcoma": 406.77, "stomatitis": 2.02, "therapeutic response decreased": 6.9, "therapy partial responder": 12.32, "thrombocytopenia": 2.96, "toxicity to various agents": 2.8, "transaminases increased": 11.0}